Literature DB >> 22478939

Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.

Niamh Higgins1, Alice Tseng, Nancy L Sheehan, Charles J L la Porte.   

Abstract

Year:  2009        PMID: 22478939      PMCID: PMC2827030          DOI: 10.4212/cjhp.v62i6.849

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


× No keyword cloud information.
  43 in total

1.  PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

Authors:  Philippe Clevenbergh; Rodolphe Garraffo; Jacques Durant; Pierre Dellamonica
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

2.  Lipid abnormalities in HIV-Infected patients and lopinavir plasma concentrations.

Authors:  Félix Gutiérrez; Sergio Padilla; Andrés Navarro; Mar Masiá; Ildefonso Hernández
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731

3.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

4.  Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Authors:  J P Dieleman; I C Gyssens; M E van der Ende; S de Marie; D M Burger
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

5.  Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Authors:  D M Burger; A M van Rossum; P W Hugen; M H Suur; N G Hartwig; S P Geelen; H J Scherpbier; R M Hoetelmans; A G Vulto; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.

Authors:  John E Ray; Debbie Marriott; Mark T Bloch; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

7.  Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.

Authors:  B M Sadler; C Gillotin; Y Lou; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

Authors:  Jintanat Ananworanich; Pope Kosalaraksa; Andrew Hill; Umaporn Siangphoe; Alina Bergshoeff; Chitsanu Pancharoen; Chulapan Engchanil; Kiat Ruxrungtham; David Burger
Journal:  Pediatr Infect Dis J       Date:  2005-10       Impact factor: 2.129

9.  Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

Authors:  R M M Cleijsen; M E van de Ende; F P Kroon; F Verduyn Lunel; P P Koopmans; L Gras; F de Wolf; D M Burger
Journal:  J Antimicrob Chemother       Date:  2007-08-17       Impact factor: 5.790

10.  Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

Authors:  Courtney V Fletcher; Hongyu Jiang; Richard C Brundage; Edward P Acosta; Richard Haubrich; David Katzenstein; Roy M Gulick
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

View more
  10 in total

1.  Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Authors:  Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong
Journal:  Can J Hosp Pharm       Date:  2012-03

Review 2.  Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

Authors:  Alice Tseng; Christine A Hughes; Janet Wu; Jason Seet; Elizabeth J Phillips
Journal:  Ann Pharmacother       Date:  2017-06-19       Impact factor: 3.154

3.  Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.

Authors:  Helena Rabie; Holly Rawizza; Peter Zuidewind; Jana Winckler; Heather Zar; Annelies Van Rie; Lubbe Wiesner; Helen McIlleron
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

4.  Is Routine Therapeutic Drug Monitoring of Anti-Retroviral Agents Warranted in Children Living with HIV?

Authors:  Jennifer Tam; Elaine Lau; Stanley Read; Ari Bitnun
Journal:  J Pediatr Pharmacol Ther       Date:  2022-08-19

5.  Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.

Authors:  Chun-Yuan Lee; Hui-Min Chang; Calvin M Kunin; Susan Shin-Jung Lee; Yao-Shen Chen; Hung-Chin Tsai
Journal:  BMC Infect Dis       Date:  2017-04-11       Impact factor: 3.090

6.  Prevalence and Associations of Psychological Distress, HIV Infection and HIV Care Service Utilization in East Zimbabwe.

Authors:  Malebogo Tlhajoane; Jeffrey W Eaton; Albert Takaruza; Rebecca Rhead; Rufurwokuda Maswera; Nadine Schur; Lorraine Sherr; Constance Nyamukapa; Simon Gregson
Journal:  AIDS Behav       Date:  2018-05

7.  Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.

Authors:  Allan Buzibye; Joseph Musaazi; Amrei von Braun; Sarah Nanzigu; Christine Sekaggya-Wiltshire; Andrew Kambugu; Jan Fehr; Mohammed Lamorde; Ursula Gutteck; Daniel Muller; Stefanie Sowinski; Steven J Reynolds; Barbara Castelnuovo
Journal:  AIDS Res Ther       Date:  2019-12-06       Impact factor: 2.250

Review 8.  Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine.

Authors:  Vanessa P Gaspar; Sahar Ibrahim; René P Zahedi; Christoph H Borchers
Journal:  J Mass Spectrom       Date:  2021-11-04       Impact factor: 1.982

9.  Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: a 5-year study.

Authors:  María Jesús Hernández Arroyo; Salvador Enrique Cabrera Figueroa; Rosa Sepúlveda Correa; María de la Paz Valverde Merino; Alicia Iglesias Gómez; Alfonso Domínguez-Gil Hurlé
Journal:  Patient Prefer Adherence       Date:  2013-08-01       Impact factor: 2.711

10.  Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.

Authors:  Selemani Saidi Sungi; Eliford Ngaimisi; Nzovu Ulenga; Philip Sasi; Sabina Mugusi
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-23       Impact factor: 2.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.